Evidence map›Paper›PMID 26988126›Full record

ArticleMethods (San Diego, Calif.)2016

Structural and functional assessment of APOBEC3G macromolecular complexes.

Bogdan Polevoda, William M McDougall, Ryan P Bennett, Jason D Salter, Harold C Smith

Abstract read
In one paragraph

Article in Methods (San Diego, Calif.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Bogdan PolevodaDepartment of Biochemistry and Biophysics, University of Rochester, School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA.
William M McDougallDepartment of Biochemistry and Biophysics, University of Rochester, School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA.
Ryan P BennettOyaGen, Inc, Rochester BioVenture Center, 77 Ridgeland Road, Rochester, NY 14623, USA.
Jason D SalterOyaGen, Inc, Rochester BioVenture Center, 77 Ridgeland Road, Rochester, NY 14623, USA.
Harold C SmithDepartment of Biochemistry and Biophysics, University of Rochester, School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA; Wilmot Cancer Institute, 601 Elmwood Avenue, Rochester, NY 14642, USA; Center for RNA Biology, 601 Elmwood Avenue, Rochester, NY 14642, USA; OyaGen, Inc, Rochester BioVenture Center, 77 Ridgeland Road, Rochester, NY 14623, USA; Center for AIDS Research, 601 Elmwood Avenue, Rochester, NY 14642, USA. Electronic address: harold.smith@rochester.edu.
University of Rochester · USOyaGen (United States) · US

Funding

Training in Cellular, Biochemical and Molecular SciencesT32GM068411 · NIGMS · UNIVERSITY OF ROCHESTER · PI MAQUAT, LYNNE E · 2005 to 2019
$3.9M
Training in HIV Replication and PathogenesisT32AI049815 · NIAID · UNIVERSITY OF ROCHESTER · PI WEDEKIND, JOSEPH E · 2001 to 2020
$3.5M
Discovery of Chemical Probes for RNA-Binding Protein Host Defense FactorsR01GM110119 · NIGMS · OYAGEN, INC. · PI SMITH, HAROLD C · 2015 to 2017
$1.8M
Identification of Antagonists of the Molecular Chaperone Function of CBF betaR01GM110568 · NIGMS · OYAGEN, INC. · PI SMITH, HAROLD C · 2013 to 2015
$1.4M
METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITINGR01DK043739 · NIDDK · UNIVERSITY OF ROCHESTER · PI SMITH, HAROLD C · 1992 to 2003
$1.1M
The Role of mRNA Editing in B Cell DevelopmentR21AI054369 · NIAID · UNIVERSITY OF ROCHESTER · PI SMITH, HAROLD C · 2003 to 2004
$473k
Based deamination by CEM15 suppresses HIV-1 InfectivityR21AI058789 · NIAID · UNIVERSITY OF ROCHESTER · PI SMITH, HAROLD C · 2004 to 2005
$468k
Development of a Novel HIV/AIDS Therapeutic Activating the APOBEC3G Host DefenseR21AI095007 · NIAID · OYAGEN, INC. · PI SMITH, HAROLD C · 2011 to 2012
$462k
Development of a High Throughput Screen for Antagonists of Vif DimerizationR21NS067671 · NINDS · OYAGEN, INC. · PI SMITH, HAROLD C · 2009 to 2011
$161k
NIAID NIH HHS R21 AI054369NIAID NIH HHS R21 AI058789NIAID NIH HHS R21 AI095007NIAID NIH HHS T32 AI049815NIDDK NIH HHS R01 DK043739NIGMS NIH HHS R01 GM110119NIGMS NIH HHS R01 GM110568NIGMS NIH HHS T32 GM068411NINDS NIH HHS R21 NS067671
6 · The paper itself

Abstract

There are eleven members in the human APOBEC family of proteins that are evolutionarily related through their zinc-dependent cytidine deaminase domains. The human APOBEC gene clusters arose on chromosome 6 and 22 through gene duplication and divergence to where current day APOBEC proteins are functionally diverse and broadly expressed in tissues. APOBEC serve enzymatic and non enzymatic functions in cells. In both cases, formation of higher-order structures driven by APOBEC protein-protein interactions and binding to RNA and/or single stranded DNA are integral to their function. In some circumstances, these interactions are regulatory and modulate APOBEC activities. We are just beginning to understand how macromolecular interactions drive processes such as APOBEC subcellular compartmentalization, formation of holoenzyme complexes, gene targeting, foreign DNA restriction, anti-retroviral activity, formation of ribonucleoprotein particles and APOBEC degradation. Protein-protein and protein-nucleic acid cross-linking methods coupled with mass spectrometry, electrophoretic mobility shift assays, glycerol gradient sedimentation, fluorescence anisotropy and APOBEC deaminase assays are enabling mapping of interacting surfaces that are essential for these functions. The goal of this methods review is through example of our research on APOBEC3G, describe the application of cross-linking methods to characterize and quantify macromolecular interactions and their functional implications. Given the homology in structure and function, it is proposed that these methods will be generally applicable to the discovery process for other APOBEC and RNA and DNA editing and modifying proteins.

Indexed as

APOBEC-3G DeaminaseCytidine DeaminaseHumansMultigene FamilyMultiprotein ComplexesProtein ConformationProtein Interaction MappingRNA-Binding ProteinsRNA EditingAPOBEC-3G DeaminaseAPOBEC3G protein, humanCytidine DeaminaseMultiprotein ComplexesRNA-Binding Proteins

Identifiers

PMID26988126
PMCPMC5014647
OpenAlexW2300874306

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.